Literature DB >> 8133154

The mechanism of thrombocytopenia in patients with HIV infection.

Y Najean1, J D Rain.   

Abstract

From a retrospective analysis of 85 patients with thrombocytopenia and HIV infection, in whom platelet production and destruction were studied by isotopic methods, the following conclusions are drawn. In most recently infected patients thrombocytopenia is due to accelerated platelet destruction; in these patients the platelet sequestration is predominantly splenic, and splenectomy is usually effective. The same pattern is seen in approximately one third of patients with more advanced disease (i.e., those with AIDS-related complex or frank AIDS). In most patients with AIDS-related complex or AIDS, the thrombocytopenia is due chiefly to a platelet production defect; splenectomy is less likely to help and is thus generally inadvisable. When the patients who were receiving zidovudine were examined separately, they were found to have a lesser rate of platelet destruction but also to have a more prominent defect in platelet production defect. This suggests that the drug may help blunt platelet destruction but may do so at a price in marrow response to the thrombocytolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8133154

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  10 in total

1.  Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway.

Authors:  Michael Nardi; Steven J Feinmark; Liang Hu; Zongdong Li; Simon Karpatkin
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages.

Authors:  Davide Gibellini; Alberto Clò; Silvia Morini; Anna Miserocchi; Cristina Ponti; Maria Carla Re
Journal:  World J Virol       Date:  2013-05-12

Review 3.  Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replication.

Authors:  S C Zell; K Peterson
Journal:  West J Med       Date:  1997-12

4.  Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.

Authors:  Zongdong Li; Michael A Nardi; Simon Karpatkin
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

5.  Platelet decline: an early predictive hematologic marker of simian immunodeficiency virus central nervous system disease.

Authors:  Lynn M Wachtman; Patrick M Tarwater; Suzanne E Queen; Robert J Adams; Joseph L Mankowski
Journal:  J Neurovirol       Date:  2006-02       Impact factor: 2.643

6.  HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia.

Authors:  J Wang; W Zhang; M A Nardi; Z Li
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

7.  Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients.

Authors:  M Nardi; S Karpatkin
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

8.  Platelet count kinetics following interruption of antiretroviral treatment.

Authors:  Eva Zetterberg; Jacqueline Neuhaus; Jason V Baker; Charurut Somboonwit; Josep M Llibre; Adrian Palfreeman; Maria Chini; Jens D Lundgren
Journal:  AIDS       Date:  2013-01-02       Impact factor: 4.177

Review 9.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

10.  Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia.

Authors:  Thomas A O'Bryan; Jason F Okulicz; William P Bradley; Anuradha Ganesan; Xun Wang; Brian K Agan
Journal:  BMC Res Notes       Date:  2015-10-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.